Kintara Therapeutics, Inc. Stock Price, News & Analysis

Kintara Therapeutics, Inc. (Nasdaq: KTRA), based in San Diego, announced that CEO Robert E. Hoffman will present a corporate overview at the MedInvest Oncology Investor Conference, from December 7-10, 2021. Hoffman's presentation is scheduled for December 9 at 2:50 p.m. EST, and he will be available for one-on-one meetings during the event. Kintara is focused on developing innovative cancer therapies, including VAL-083 for Glioblastoma Multiforme and REM-001 for Cutaneous Metastatic Breast Cancer, both of which are in late-stage clinical development.

Kintara Therapeutics (Nasdaq: KTRA) announced the activation of its VAL-083 treatment arm in the Global Coalition for Adaptive Research (GCAR) Phase 2/3 clinical trial for glioblastoma multiforme at Sunnybrook Health Sciences Centre in Toronto. As of November 24, 2021, Kintara is actively recruiting at 30 U.S. sites, with plans to enroll 150-200 patients across over 40 sites. The GBM AGILE trial aims to identify effective therapies for GBM and may expedite FDA submissions. The company is also advancing other late-stage therapies for unmet medical needs.

Kintara Therapeutics (Nasdaq: KTRA) has presented promising results from two Phase 2 studies of VAL-083 for treating glioblastoma multiforme (GBM) at the Society for Neuro-Oncology Annual Meeting. In one study, newly diagnosed patients showed a median overall survival (mOS) of 19.1 months and a progression-free survival (PFS) of 8.7 months, outperforming historical controls. The second study reported an mOS of 8.0 months in recurrent GBM patients. Both studies reported myelosuppression as the most common adverse effect. Kintara is advancing VAL-083 for GBM and REM-001 for CMBC.

Kintara (Nasdaq: KTRA) reported its fiscal first-quarter results for the period ending September 30, 2021. The company had cash and cash equivalents of approximately $19.3 million and a net loss of about $6.0 million, significantly reduced from $19.5 million in the same quarter last year. Kintara highlighted progress in its clinical trials for VAL-083 in glioblastoma and REM-001 for breast cancer, with significant data indicating progression-free survival rates. Additionally, it raised $15.0 million from institutional investors for ongoing studies.

Kintara Therapeutics (Nasdaq: KTRA) will present at the Q4 Investor Summit Conference on November 17, 2021, at 1:15 p.m. ET. CEO Robert E. Hoffman will provide a corporate overview and is available for one-on-one meetings throughout the event. The company is focused on developing novel therapies for rare cancers, with two Phase 3-ready treatments: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Kintara's VAL-083 has shown clinical promise across multiple cancers, while REM-001 displays an 80% efficacy in prior studies.

Kintara (Nasdaq: KTRA) announced a leadership change on November 8, 2021, with Robert E. Hoffman succeeding Saiid Zarrabian as President and CEO. Hoffman will retain his role as Chairman, while Zarrabian transitions to leading strategic partnerships. This change is positioned as a pivotal moment as Kintara prepares for the final stages of clinical development for VAL-083, crucial for treating glioblastoma. The company aims to expedite regulatory submission timelines by participating in the FDA-approved GBM AGILE study, with sufficient funding secured through stage 1 of the trial.

Kintara Therapeutics (Nasdaq: KTRA) will be presenting at the 14th Annual LD Micro Main Event Conference held in Los Angeles from October 12-14, 2021. CEO Saiid Zarrabian is scheduled to deliver a corporate overview on October 12 at 2:00 p.m. PT. Kintara focuses on developing innovative cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. The presentation will highlight Kintara’s advancements in clinical trials and therapeutic development.

Kintara (Nasdaq: KTRA) reported its fiscal year 2021 financial results, highlighting a net loss of approximately $38.3 million, or $1.60 per share, up from a loss of $9.1 million in 2020. The company successfully raised $15 million through a registered direct offering and advanced patient enrollment in its GBM AGILE study with 26 clinical trial sites activated. Notable safety and efficacy results for its therapy VAL-083 were reported from Phase 2 studies, demonstrating promising progression-free survival.

Kintara Therapeutics announced the closing of a registered direct offering, raising approximately $15 million from the sale of 12 million shares of common stock and associated warrants priced at $1.25 each. The proceeds will fund clinical studies and general corporate purposes. The offering was facilitated by H.C. Wainwright & Co. The company is focused on developing innovative cancer therapies, notably VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer. Kintara's research includes promising clinical trial results for its therapies.